Biotech Firms Race to Treat Aging Itself Using Living Cell Therapies
A new wave of biotechs is targeting aging as a root cause, using encapsulated cells and gene therapy to restore lost proteins and reverse decline.
Summary
A growing number of biotech companies are shifting focus from individual diseases to aging itself as the underlying condition. Leading this wave is Avaí Bio, which is developing encapsulated genetically modified cells that continuously produce α-Klotho, a protein that declines with age and is linked to cardiovascular health, bone density, and cognitive function. Rather than daily drug dosing, the approach implants a self-sustaining protein factory inside the body. Other companies are pursuing parallel strategies: Lineage Cell Therapeutics is scaling cell platforms for diabetes, Ocugen reported a 46% reduction in macular degeneration lesion growth via gene therapy, and Vertex Pharmaceuticals showed early stem-cell diabetes patients reducing or eliminating insulin use. The longevity biotech market is projected to nearly triple to $29.7 billion by 2034.
Detailed Summary
Aging has long been treated as a backdrop to disease rather than a condition in its own right. That framing is now being challenged by a new generation of biotech companies building therapies that target the biology of aging directly, using living cells and gene-based tools rather than conventional drugs.
At the center of this report is α-Klotho, a protein that declines naturally with age and whose loss is associated with accelerated cardiovascular damage, bone deterioration, and cognitive decline. Avaí Bio, working through a joint venture called Klothonova with Austrianova, is engineering genetically modified cells to continuously produce α-Klotho inside the body. These cells are enclosed in protective capsules designed to evade immune destruction, functioning as a long-term internal protein source. New data from this program is expected at the Second Annual Klotho Conference in September 2026.
The Klotho approach is compelling because the protein influences multiple aging pathways simultaneously. In animal models, elevated Klotho levels correlate with longer lifespans and better systemic function. However, translating these findings to humans remains difficult due to protein instability, complex delivery challenges, and the multifactorial nature of aging biology.
Beyond Klotho, the article highlights a broader industry pattern. Ocugen's gene therapy showed a 46% reduction in lesion growth in age-related macular degeneration. Vertex Pharmaceuticals reported that most early-stage Type 1 diabetes patients receiving stem-cell-derived therapy were able to reduce or eliminate insulin dependence, suggesting functional reversal rather than mere management. Lineage Cell Therapeutics is addressing scalability bottlenecks in therapeutic cell production.
The longevity biotech market, valued at $9.86 billion in 2025, is projected to reach $29.7 billion by 2034. While these developments are early-stage and largely pre-clinical or in initial human trials, the convergence of capital, scientific interest, and novel delivery platforms signals a meaningful shift in how aging-related disease may be treated within the next decade.
Key Findings
- α-Klotho declines with age and is linked to cardiovascular, bone, and cognitive decline across multiple systems
- Encapsulated genetically modified cells may continuously produce α-Klotho inside the body, avoiding daily dosing
- Ocugen's gene therapy showed a 46% reduction in age-related macular degeneration lesion growth in early data
- Vertex stem-cell therapy enabled most Type 1 diabetes patients to reduce or eliminate insulin use
- Longevity biotech market projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034
Methodology
This is an industry news report from Longevity.Technology, a specialist publication covering aging science and biotech. It synthesizes multiple company announcements and early-stage clinical signals rather than reporting a single peer-reviewed study. Evidence basis is largely preclinical or early human trial data; one market projection figure is cited with a reference number but the primary source is not named in the excerpt.
Study Limitations
The article is a news overview and does not provide full trial data, sample sizes, or peer-reviewed citations for most claims. The Klotho encapsulated cell program has not yet published human data. Market projections should be treated as estimates. Readers should consult primary sources and clinical trial registries for verification of efficacy and safety claims.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.